Phase 3 N=22,220 Study of Vitamin D and Omega-3 Supplementation for Preventing Diabetes
Type 2 Diabetes
Primary: Incident Type 2 Diabetes — 121; 109; 139; 115 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=120 Mindfulness-Based Intervention for Depression and Insulin Resistance in Adolescents
Type 2 Diabetes · Depression · Insulin Resistance
Primary: Intervention Fidelity — 90; 90; 97.5; 100 Expert ratings ranging from 0-100%
N/A N=596 A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA
Urothelial Carcinoma
Primary: Overall Survival (OS): Overall — 21.3 Months
Early Phase 1 N=25 Contrast-Enhanced Ultrasound Scan for the Estimation of Tissue Pressure in Patients With Breast Cancer
Breast Carcinoma
Primary: Correlation Between Subharmonic Aided Pressure Estimation (SHAPE) Results and Direct Measurements of Interstitial Fluid Pressure (IFP) — 0.2 Correlation coefficient…
Phase 2 N=74 Sing For Your Saunter Part 2 R33
Parkinson Disease
Primary: Gait Speed — 1.09; 1.04; 1.15; 1.08 meters per second
Phase 2 N=5 A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders
Hematologic Neoplasm · Neoplasms · Hematologic Malignancies
Primary: Number of Participants With Treatment Emergent Adverse Events — 1; 1; 1; 1 Participants
N/A N=88 Pelvic Floor Shear-Wave Elastography in Healthy and Pudendal Neuralgia Women
Pudendal Nerve · Healthy Women
Primary: Superficial Pelvic Floor Muscle (Bulbospongiosus, Ischiocavernosus, Superficial Transverse Perineal Muscles)Stiffness (kPa) Measured by Shear-wave Elastography — 612…
Phase 2 N=13 SNIFF Multi-Device Study 2
Mild Cognitive Impairment · Cognitive Impairment
Primary: Cerebrospinal Fluid Insulin Levels — 0.11; 0.15; 0.14; 0.26 micro units/mL
N/A N=135 Human Participant Study of Prototype Non-medicated Multilayer Foam Dressings on Intact Skin
Healthy
Primary: Number of Participants With Acceptable Dressing Presence at Day 7 — 48; 23; 35; 27 Participants
Phase 4 N=66 Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of Age
Hunter Syndrome
Primary: Height Overall — 113.759; 108.143 centimeter (cm) — p== 0.011
Phase 2 N=147 Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors
Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in · HNSCC for Phase 2 Dose Expansion · NSCLC for Phase 2 Dose Expansion
Primary: Phase 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 1; 1; 3; 5 Participants
N/A N=54 Ketone Ester Effects on Biomarkers of Brain Metabolism and Cognitive Performance in Cognitively Intact Adults 55 Years Old or Older
Metabolic Syndrome · Normal Cognition
Primary: Change in β-hydroxybutyrate in the Posteromedial Cortex Measured by ¹H-MRS (PRESS) — 1.847; 0.922; 1.265; 1.172 Ratio
Phase 4 N=40 VENLID: The Application of a 10%-Lidocaine Spray Prior to the Insertion of a Peripheral Intra-venous Catheter in Female Adults
Pain
Primary: Pain Difference Caused by PIVC (Peripheral Intravenous Catheter) Rated by NRS (Numeric Rating Scale) Between Application of 10% Licocaine Spray and Placebo-for the…
Phase 1 N=42 Piloting Movement-to-Music With Arm-based Sprint-Intensity Interval Training Among Children With Physical Disabilities
Cerebral Palsy
Primary: Changes in pVO2 — 1.72; -0.61 mL/kg-1/min-1
N/A N=109 COPD Access to Pulmonary Rehabilitation Intervention
COPD
Primary: Physical Activity Measured as Change in Average Daily Step Count — 1302.34; -108.15 steps per day — p=0.005